ライフサイエンスコーパス: schizoaffective disorder

1 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

2 spectrum disorders (mostly schizophrenia and schizoaffective disorder).

3 ht outpatients with chronic schizophrenia or schizoaffective disorder.

4 h analysis of 4084 samples with BPAD, SZ, or schizoaffective disorder.

5 and cognitive functions in schizophrenia and schizoaffective disorder.

6 asive nicotinic effects in schizophrenia and schizoaffective disorder.

7 ican American probands with schizophrenia or schizoaffective disorder.

8 r predisposition genes for schizophrenia and schizoaffective disorder.

9 e treatment of early-onset schizophrenia and schizoaffective disorder.

10 e for treating early-onset schizophrenia and schizoaffective disorder.

11 olescents with early-onset schizophrenia and schizoaffective disorder.

12 otics to treat early-onset schizophrenia and schizoaffective disorder.

13 tpatients with diagnoses of schizophrenia or schizoaffective disorder.

14 age and older patients with schizophrenia or schizoaffective disorder.

15 ficacy in the treatment of schizophrenia and schizoaffective disorder.

16 e intron 1/exon 2 region in individuals with schizoaffective disorder.

17 acutely ill inpatients with schizophrenia or schizoaffective disorder.

18 tion of the exon 9 missense allele Phe607 in schizoaffective disorder.

19 patients with diagnoses of schizophrenia or schizoaffective disorder.

20 ent of the first episode of schizophrenia or schizoaffective disorder.

21 cs of ASP4345 in patients with schizophrenia/schizoaffective disorder.

22 with acute exacerbation of schizophrenia or schizoaffective disorder.

23 e and negative symptoms in schizophrenia and schizoaffective disorder.

24 ressive disorder (MDD), bipolar disorder, or schizoaffective disorder.

25 nt of patients with chronic schizophrenia or schizoaffective disorder.

26 f relapse in patients with schizophrenia and schizoaffective disorder.

27 dividuals with recent-onset schizophrenia or schizoaffective disorder.

28 cognition in patients with schizophrenia or schizoaffective disorder.

29 ords of 82 outpatients with schizophrenia or schizoaffective disorder.

30 ponse to a first episode of schizophrenia or schizoaffective disorder.

31 ry from a first episode of schizophrenia and schizoaffective disorder.

32 a major depressive episode or diagnosed with schizoaffective disorder.

33 behavior in patients with schizophrenia and schizoaffective disorder.

34 th a DSM-III-R diagnosis of schizophrenia or schizoaffective disorder.

35 ive-compulsive disorder and schizophrenia or schizoaffective disorder.

36 with a primary diagnosis of schizophrenia or schizoaffective disorder.

37 up (68% of survivors); 175 had schizophrenia/schizoaffective disorder.

38 rge among 151 patients with schizophrenia or schizoaffective disorder.

39 42 drug-free patients with schizophrenia or schizoaffective disorder.

40 percentage of patients with schizophrenia or schizoaffective disorder.

41 disorder and 38% of the treatments used for schizoaffective disorder.

42 ume was found in patients with schizophrenia/schizoaffective disorder.

43 sfunction in patients with schizophrenia and schizoaffective disorder.

44 years of age or older with schizophrenia or schizoaffective disorder.

45 cluded 287 individuals with schizophrenia or schizoaffective disorder.

46 he abnormalities were similar between SZ and schizoaffective disorder.

47 hotic disorders, including schizophrenia and schizoaffective disorders.

48 d group of 21 subjects with schizophrenia or schizoaffective disorder, 11 subjects with schizotypal p

49 disorder with psychosis and schizophrenia or schizoaffective disorder), 192 presenting with a primary

50 randomization, 58.1% had schizophrenia or a schizoaffective disorder, 22.0% had bipolar disorder, an

51 ducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory

52 reviously reported): 19 patients with SCZ or schizoaffective disorder, 30 unaffected first-degree rel

53 ere psychosis not otherwise specified (44%), schizoaffective disorder (36%), and brief psychosis (27%

54 g pairs with a diagnosis of schizophrenia or schizoaffective disorder, 396 highly polymorphic markers

55 ohort, 4310 developed bipolar disorder; 784, schizoaffective disorder; 4823, schizophrenia; and 5013,

56 .5% met DSM-IV criteria for schizophrenia or schizoaffective disorder; 55.8%, for major affective dis

57 comprising 42 patients with schizophrenia or schizoaffective disorder, 57 of their unaffected first-d

58 ence; 64 men with DSM-III-R schizophrenia or schizoaffective disorder; 62 men with Research Diagnosti

59 a (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to

60 samples (528 UK patients with schizophrenia/schizoaffective disorder; 921 German participants includ

61 s: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad

62 A total of 18 treatment studies of schizoaffective disorder and 15 of schizophrenia with mo

63 out including 10,925 cases with BPAD, SZ, or schizoaffective disorder and 16,747 controls.

64 Eighteen individuals with schizophrenia or schizoaffective disorder and 19 healthy control particip

65 nsisted of 23 patients with schizophrenia or schizoaffective disorder and 19 non-psychiatric voluntee

66 nts in the first episode of schizophrenia or schizoaffective disorder and 22 healthy comparison subje

67 Twenty-seven patients with schizophrenia or schizoaffective disorder and 23 healthy controls.

68 In 24 patients with schizophrenia or schizoaffective disorder and 25 healthy comparison subje

69 with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder and 26 healthy volunteers parti

70 ata for 3,945 subjects with schizophrenia or schizoaffective disorder and 3,611 screened comparison s

71 tudied 127 outpatients with schizophrenia or schizoaffective disorder and 30 healthy comparison subje

72 relates in 33 patients with schizophrenia or schizoaffective disorder and 31 healthy comparison subje

73 Forty-four patients with schizophrenia or schizoaffective disorder and 34 healthy comparison subje

74 tal cortex from 37 people with schizophrenia/schizoaffective disorder and 37 matched controls.

75 ged and older patients with schizophrenia or schizoaffective disorder and 38 normal comparison subjec

76 essed in 149 consumers with schizophrenia or schizoaffective disorder and 50 healthy control subjects

77 ort of 524 individuals with schizophrenia or schizoaffective disorder and 573 control subjects.

78 ction from 62 subjects with schizophrenia or schizoaffective disorder and 62 matched healthy comparis

79 a subset of 59 people with schizophrenia or schizoaffective disorder and 65 healthy controls, and pr

80 the plasma of 78 patients with schizophrenia/schizoaffective disorder and 73 healthy controls.

81 dication-free patients with schizophrenia or schizoaffective disorder and 74 healthy comparison indiv

82 btained from 96 people with schizophrenia or schizoaffective disorder and 83 healthy controls.

83 , 18-51 years; 59 men) with schizophrenia or schizoaffective disorder and 87 healthy controls (mean [

84 0) sibling pair studies of schizophrenia and schizoaffective disorder and a comparable study of bipol

85 medicated, outpatients with schizophrenia or schizoaffective disorder and a Repeatable Battery for th

86 psychiatric disorders, mainly schizophrenia, schizoaffective disorder and bipolar disorder.

87 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

88 individuals diagnosed with schizophrenia or schizoaffective disorder and in 197 healthy comparison s

89 men comorbid for DSM-III-R schizophrenia or schizoaffective disorder and lifetime alcohol abuse or d

90 d lifetime rates were found in patients with schizoaffective disorder and major depression with psych

91 ants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity des

92 ction from 36 subjects with schizophrenia or schizoaffective disorder and matched normal comparison s

93 Twenty-four patients with schizophrenia or schizoaffective disorder and medication-resistant AHs we

94 atients with first-episode schizophrenia and schizoaffective disorder and potential predictors of res

95 who met DSM-IV criteria for schizophrenia or schizoaffective disorder and retrospective and prospecti

96 A boundary between schizoaffective disorder and schizophrenia was not obser

97 h diagnoses of bipolar disorder, depression, schizoaffective disorder and schizophrenia).

98 met DSM-III-R criteria for schizophrenia or schizoaffective disorder and their co-twins without psyc

99 viduals with DSM-IV-defined schizophrenia or schizoaffective disorder and their mothers underwent a 4

100 o overlapping groups of patients: those with schizoaffective disorder and those with schizophrenia an

101 Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized w

102 nsider 166 persons who have schizophrenia or schizoaffective disorder and who have had either their g

103 mple included 1,870 cases (schizophrenia and schizoaffective disorder) and 2,002 screened comparison

104 SZ (including a subgroup diagnosed as having schizoaffective disorder) and 26 age-matched and sex-mat

105 bipolar disorder with psychotic features, or schizoaffective disorder, and 10,195 population control

106 h psychosis (146 with schizophrenia, 90 with schizoaffective disorder, and 115 with psychotic bipolar

107 with schizophrenia, 106 of individuals with schizoaffective disorder, and 129 of individuals with ps

108 tients with schizophrenia, 103 patients with schizoaffective disorder, and 129 patients with psychoti

109 nts met DSM-IV criteria for schizophrenia or schizoaffective disorder, and 21 nonpsychiatric voluntee

110 atients with schizophrenia, 32 patients with schizoaffective disorder, and 40 patients with bipolar d

111 ely 65% of participants had schizophrenia or schizoaffective disorder, and 85.5% were receiving conco

112 Schizophrenia, schizoaffective disorder, and bipolar disorder are commo

113 collected on individuals with schizophrenia, schizoaffective disorder, and bipolar disorder with psyc

114 nd exon 9 are associated with schizophrenia, schizoaffective disorder, and bipolar disorder.

115 nical phenotype of psychosis (schizophrenia, schizoaffective disorder, and bipolar I disorder with ps

116 People with schizophrenia, schizoaffective disorder, and bipolar illness share clin

117 Heritability estimates for schizophrenia, schizoaffective disorder, and mania were substantial and

118 sychotic disorders (including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder

119 bipolar I, bipolar II with major depression, schizoaffective disorder, and recurrent unipolar disorde

120 bipolar disorder, major depressive disorder, schizoaffective disorder, and schizophrenia) in male par

121 ntal illness (defined here as schizophrenia, schizoaffective disorders, and bipolar affective disorde

122 nergic mechanisms to treat schizophrenia and schizoaffective disorder appears indicated.

123 Bipolar, schizophrenia, and schizoaffective disorders are common, highly heritable p

124 Established nosology identifies schizoaffective disorder as a distinct category with bou

125 assess the rationale for the continuation of schizoaffective disorder as a legitimate diagnostic cate

126 were diagnosed with either schizophrenia or schizoaffective disorder as defined by the DSM-IV.

127 me, however, have questioned the validity of schizoaffective disorder as separate from psychotic mood

128 probands (63 with schizophrenia and 12 with schizoaffective disorder), ascertained so as to be repre

129 probands (60 with schizophrenia and 12 with schizoaffective disorder, ascertained so as to be repres

130 meeting DSM-IV criteria for schizophrenia or schizoaffective disorder, assessed during acute admissio

131 attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide.

132 mately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximat

133 Subtypes of BD including schizoaffective disorder bipolar type (SAB), bipolar I d

134 and three psychotic disorders--schizophrenia/schizoaffective disorder, bipolar disorder with psychosi

135 ss as a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or other psy

136 9), bipolar disorder (DSM-IV-TR) (N=40), and schizoaffective disorder, bipolar type (N=18).

137 probands with bipolar I disorder (N=192) and schizoaffective disorder, bipolar type, (N=11) were incl

138 bipolar I disorder; bipolar II disorder; or schizoaffective disorder, bipolar type, according to DSM

139 ion to antipsychotic action in patients with schizoaffective disorder, bipolar type, and bipolar I di

140 nd bipolar disorder and parses patients with schizoaffective disorder, bipolar type, into two subgrou

141 d aim was to determine whether subjects with schizoaffective disorder, bipolar type, were neurophysio

142 ive disorder and a sibling with bipolar I or schizoaffective disorder, bipolar type.

143 is of a major affective disorder (BP type I; schizoaffective disorder, bipolar type; BP type II; or m

144 nts with either bipolar disorder (N = 10) or schizoaffective disorder-bipolar subtype (N = 15) for wh

145 models (ASMs) were considered: ASM1 (BPI and schizoaffective disorder, BP cases (SABP) only), ASM2 (A

146 arrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control

147 RNA levels were 13.6% lower in subjects with schizoaffective disorder but did not differ in subjects

148 dysregulation of calreticulin homeostasis in schizoaffective disorder by both genetic and functional

149 SZ: OR = 2.40, p = 1.3 x 10(-4); SZ, BD, and schizoaffective disorder combined: OR = 1.87, p = 8 x 10

150 Twenty-six patients with schizophrenia and schizoaffective disorder completed a task requiring alte

151 patients with diagnoses of schizophrenia or schizoaffective disorder) completed the Sternberg Item-R

152 The diagnosis of schizoaffective disorder depends on the disease specific

153 and in patients with schizophrenia (N=12) or schizoaffective disorder, depressed type (N=4), during a

154 nostic Criteria major depressive disorder or schizoaffective disorder, depressed type, entered a long

155 atients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type.

156 A 40-yr-old woman with a diagnosis of schizoaffective disorder developed catatonia in the cont

157 rge among 151 patients with schizophrenia or schizoaffective disorder diagnosed according to Research

158 Cases with diagnoses of schizophrenia or schizoaffective disorder (DSM-IIIR criteria) were consid

159 hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blin

160 The patients with schizophrenia or schizoaffective disorder exhibited less accuracy and spe

161 henotypes for probands with schizophrenia or schizoaffective disorder (extensive neocortical or subco

162 ID1) met this criterion for schizophrenia or schizoaffective disorder; five replicate previous associ

163 The schizophrenia or schizoaffective disorder group exhibited decreased power

164 The schizoaffective disorder group was split, with six subje

165 the schizophrenia, simple schizophrenia, and schizoaffective disorder group were inversely related (b

166 The diagnosis of schizoaffective disorder has long maintained an uncertai

167 n this mutation in the calreticulin gene and schizoaffective disorder has remained speculative.

168 ents with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if

169 atients with first-episode schizophrenia and schizoaffective disorder have high rates of response to

170 However, because most prior studies of schizoaffective disorder have only evaluated differences

171 2q11 microdeletions develop schizophrenia or schizoaffective disorder in adolescence and adulthood.

172 iated with the diagnosis of schizophrenia or schizoaffective disorder in the white subset of the stud

173 revious studies, these findings suggest that schizoaffective disorder is associated with lower levels

174 uggest that negative affect in schizophrenia/schizoaffective disorder is associated-directly or indir

175 s of rarity between them and suggesting that schizoaffective disorder is not a separate, 'bona-fide'

176 r, the interrater reliability for diagnosing schizoaffective disorder is very low.

177 Patients diagnosed with schizoaffective disorder likely suffer from a psychotic

178 Research Diagnostic Criteria schizophrenia, schizoaffective disorder, mania, DSM-III-R schizophrenia

179 y greater from bipolar disorder (z=-0.77) to schizoaffective disorder (manic z=-1.08; depressed z=-1.

180 (N=293), psychotic bipolar disorder (N=227), schizoaffective disorder (manic, N=110; depressed, N=55)

181 -six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and

182 Contrary to earlier formulations, schizoaffective disorder may be a more severe form of il

183 that hippocampal volume in schizophrenia or schizoaffective disorder may be linked to time of diseas

184 These results suggest that schizoaffective disorder may possess distinct features.

185 outpatients diagnosed with schizophrenia or schizoaffective disorder (mean [SD] age, 46 [11] years;

186 In the subjects with schizoaffective disorder, mean GAD65 protein levels were

187 7); schizophrenia, simple schizophrenia, and schizoaffective disorder (n = 178); and all nonaffective

188 Patients with schizophrenia (N = 52) or schizoaffective disorder (N = 25) were evaluated for the

189 ients diagnosed with schizophrenia (n = 49), schizoaffective disorder (n = 37), or bipolar disorder w

190 eting criteria for schizophrenia (n = 19) or schizoaffective disorder (n = 7) and 26 healthy controls

191 isorder (n = 37), schizophrenia (n = 29), or schizoaffective disorder (n = 8).

192 ollow-Up Study with schizophrenia (N = 187), schizoaffective disorder (N = 87), schizophreniform diso

193 s in their first episode of schizophrenia or schizoaffective disorder (N=118) were assessed at baseli

194 cording to DSM-IV as having schizophrenia or schizoaffective disorder (N=155), bipolar disorder with

195 nth follow-up to patients with schizophrenia/schizoaffective disorder (N=225), bipolar disorder with

196 e offspring of mothers with schizophrenia or schizoaffective disorder (N=26) and matched comparison m

197 ed for nonpsychotic bipolar disorder (N=68), schizoaffective disorder (N=31), or schizophrenia (N=536

198 Adults with schizophrenia or schizoaffective disorder (N=481) were randomly assigned

199 icated patients with schizophrenia (N=61) or schizoaffective disorder (N=6).

200 ection sites, patients with schizophrenia or schizoaffective disorder (N=610), their biological relat

201 [65%]), bipolar disorder (n=115 [22%]), and schizoaffective disorder (n=66 [13%]).

202 psychotic disorders (schizophrenia, n = 219; schizoaffective disorder, n = 142; and psychotic bipolar

203 phrenia spectrum disorder (schizophrenia and schizoaffective disorder, n = 23) and healthy controls (

204 7 schizophrenia cases (schizophrenia, N=630; schizoaffective disorder, N=147) with maternal sera avai

205 Furthermore, patients with a diagnosis of schizoaffective disorder or a history of at least one ma

206 t of other variables, such as a diagnosis of schizoaffective disorder or medication use at the time o

207 re adult men and women with schizophrenia or schizoaffective disorder or non-psychiatric control subj

208 For acute exacerbations of schizoaffective disorder or of schizophrenia with mood s

209 trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had mod

210 o had received a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.

211 d first-degree relatives with schizophrenia, schizoaffective disorder, or bipolar disorder.

212 nths; a clinical diagnosis of schizophrenia, schizoaffective disorder, or delusional disorder; and a

213 participants with underlying schizophrenia, schizoaffective disorder, or mood disorder.

214 of patients hospitalized for schizophrenia, schizoaffective disorder, or nonpsychotic bipolar disord

215 1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder;

216 ited 933 stable probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorde

217 ients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (

218 had a DSM-III-R diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder a

219 who were later diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder,

220 ht outpatients with chronic schizophrenia or schizoaffective disorder over 16 weeks.

221 morbidity, and diagnosis of schizophrenia or schizoaffective disorder (p<0.01 for all contrasts).

222 al regions were limited to schizophrenia and schizoaffective disorders (P < .001).

223 One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, doub

224 tivity (rsfMRI) approach in 84 schizophrenia/schizoaffective disorder patients and 66 healthy compari

225 positive psychotic symptoms in schizophrenia/schizoaffective disorder patients at 24 months suggests

226 ed (125 SZ, 120 bipolar disorder [BD] and 36 schizoaffective disorder patients vs. 467 unaffected adu

227 than the other two groups, and schizophrenia/schizoaffective disorder patients with baseline panic sy

228 Finally, within the schizophrenic/schizoaffective disorder patients, smaller hippocampal v

229 Subjects with schizoaffective disorder performed significantly worse t

230 esponse were diagnosis (schizophrenia versus schizoaffective disorder), premorbid functioning, durati

231 SZ probands, n = 224; PBD probands, n = 190; schizoaffective disorder probands, n = 142; unaffected r

232 riptome signatures are not characteristic of schizoaffective disorder, providing a potential molecula

233 ome among outpatients with schizophrenia and schizoaffective disorder receiving clozapine with a matc

234 ple of 162 outpatients with schizophrenia or schizoaffective disorder recruited from four sites.

235 generally better preserved in patients with schizoaffective disorder relative to patients with schiz

236 relatives, n = 195; PBD relatives, n = 175; schizoaffective disorder relatives, n = 113]; control su

237 r disorder (RR, 0.42; 95% CI, 0.17-0.69) and schizoaffective disorder (RR, 0.44; 95% CI, 0.11-0.79) c

238 orders (107 with schizophrenia (SZ), 87 with schizoaffective disorder (SAD), 132 with psychotic bipol

239 a superimposed mood syndrome [SZ+; N = 224], schizoaffective disorder [SAD; N = 129] and bipolar I di

240 netic, reveals multiple similarities between schizoaffective disorder, schizophrenia and psychotic bi

241 Inpatient diagnoses of bipolar disorder, schizoaffective disorder, schizophrenia, and other nonaf

242 was compared between 14 patients with SCZ or schizoaffective disorder (SCZ/SAD) and 17 controls using

243 present or present to a lesser degree in the schizoaffective disorder subjects (diagnosis of schizoaf

244 in a live cohort of psychosis (schizophrenia/schizoaffective disorder) subjects.

245 (SZ), psychotic bipolar disorder (PBD), and schizoaffective disorder; their first-degree relatives;

246 iously reported linkage of schizophrenia and schizoaffective disorder to 13q32-34 in the European des

247 cal and biological features of patients with schizoaffective disorder to patients with related disord

248 able condition with chronic schizophrenia or schizoaffective disorder to receive treatment with flexi

249 we have also found linkage of schizophrenia/schizoaffective disorder to this same chromosomal region

250 patients with early-onset schizophrenia and schizoaffective disorder to treatment with either olanza

251 schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 70

252 Schizoaffective disorder unifies schizophrenia and bipol

253 In adults with schizophrenia or schizoaffective disorder, use of paliperidone palmitate

254 sensus diagnosis of schizophrenia (including schizoaffective disorder) using DSM-III or DSM-IV criter

255 Schizoaffective disorder was associated with low emotion

256 opathology in patients with schizophrenia or schizoaffective disorder was examined before and after t

257 and 63 female patients with schizophrenia or schizoaffective disorder was extensively studied and com

258 for the phenotype of DSM-IV schizophrenia or schizoaffective disorder was found in a region on chromo

259 Schizoaffective disorder was named as a compromise diagn

260 izoaffective disorder subjects (diagnosis of schizoaffective disorder was the most significant covari

261 rty-three outpatients with schizophrenia and schizoaffective disorder were categorized into deficit a

262 schizophrenia, schizophreniform disorder, or schizoaffective disorder were evaluated during their fir

263 Thirty patients with schizophrenia or schizoaffective disorder were investigated.

264 The characteristics of schizoaffective disorder were more often similar to schi

265 mRNA and protein levels within subjects with schizoaffective disorder were not attributable to factor

266 y-five patients with DSM-IV schizophrenia or schizoaffective disorder were randomly assigned for 9 mo

267 Sixty-nine people with schizophrenia or schizoaffective disorder were randomly assigned to 36 se

268 Sixty-five patients with schizophrenia or schizoaffective disorder were randomly assigned to NET p

269 who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to recei

270 outpatients with DSM-III-R schizophrenia or schizoaffective disorder were randomly assigned to recei

271 Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to recei

272 7) outpatients with chronic schizophrenia or schizoaffective disorder were randomly assigned to recei

273 lly stable outpatients with schizophrenia or schizoaffective disorder were randomly assigned to train

274 total of 181 patients with schizophrenia or schizoaffective disorder were recruited from three clini

275 SFs of the individuals with schizophrenia or schizoaffective disorder were related to those of the hu

276 n) with DSM-IV diagnoses of schizophrenia or schizoaffective disorder were selected to form two group

277 ia for treatment-refractory schizophrenia or schizoaffective disorder were studied.

278 cing their first episode of schizophrenia or schizoaffective disorder were treated first with clozapi

279 Individuals with schizophrenia or schizoaffective disorders were included as cases.

280 e (as a part of major depressive disorder or schizoaffective disorder) were at a greater risk for sui

281 ved a research diagnosis of schizophrenia or schizoaffective disorder, whereas 44% of patients with n

282 The diagnosis of schizoaffective disorder, which can result in substandar

283 tics of 52 individuals with schizophrenia or schizoaffective disorder who had attempted suicide with

284 ose of 104 individuals with schizophrenia or schizoaffective disorder who had not made a suicide atte

285 tients meeting criteria for schizophrenia or schizoaffective disorder who had residual symptoms despi

286 cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the

287 were adults diagnosed with schizophrenia or schizoaffective disorder who were clinically assessed to

288 lve patients with DSM-IV bipolar disorder or schizoaffective disorder who were clinically stable whil

289 ects were 322 patients with schizophrenia or schizoaffective disorder who were consecutively admitted

290 cing their first episode of schizophrenia or schizoaffective disorder who were given fluphenazine as

291 treatment in patients with schizophrenia and schizoaffective disorder who were hospitalized or at hig

292 d fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hos

293 ly assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state ps

294 Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine mo

295 ients with the diagnoses of schizophrenia or schizoaffective disorder who were treated with risperido

296 spectrum disorders (mostly schizophrenia and schizoaffective disorder) who had available second-trime

297 re mental illness (46% with schizophrenia or schizoaffective disorder) who had not obtained or kept c

298 Patients with schizophrenia or schizoaffective disorder with a body mass index >/= 27 a

299 ded schizophrenia, simple schizophrenia, and schizoaffective disorder with poor outcome.

300 severity continuum (schizophrenia worse than schizoaffective disorder worse than bipolar psychosis);